2015 Product Trends in Cardiovascular & Endovascular Care
Over the next several months, the FTI Consulting Cardiovascular Clinical Passport™ Team will bring you a series of articles on Cardiovascular and Endovascular Care. This first article looks at what is trending in 2015 in the Cardiology, CVOR and Endovascular spaces. Our goal is to help CFOs, supply chain executives and clinical leaders better prepare financially for the introductions of new technology in the days ahead.
Trends in Cardiac Diagnostics
- Wearable, Portable Heart Monitoring Devices. In October 2014, Medtronic launched an external, wirefree heart monitor that can be used for up to 30 days by patients who have been experiencing irregular heartbeats. The SEEQ MCT System’s suggested clinical applications are for patients who experience irregular heartbeats with associated syncope (fainting), lightheadedness, vertigo, palpitations or shortness of breath, and whose symptoms had not been previously detected through use of 24-hour Holter monitoring. Healthcare supply chain executives and cardiac services directors should be prepared to address the introduction of these products as part of their value analysis processes.
- Left Atrial Appendage Occluder (LAA) Devices. In March 2015, Boston Scientific‘s Watchman™ Left Atrial Appendage Occluder (LAA) – currently commercially available in 55 countries for the treatment of patients with non-valvular atrial fibrillation – was cleared by the FDA for distribution in the United States. The Watchman™ device has been successfully implanted in over 7000 patients worldwide experiencing recurring non-heart valve related atrial fibrillation. Patients with non-valvular atrial fibrillation are at higher risk for blood clots breaking loose and settling in the brain, heart or lungs causing strokes, coronary myocardial infarctions or pulmonary emboli. Boston Scientific’s The WATCHMAN™ is a three-part system consisting of a transceptal access sheath, a delivery catheter, and a self-expanding nitrol framed device with fixation barbs and permeable polyester fabric covering the atrial facing surface of the device. The WATCHMAN™ could provide US physicians alternative treatment regimes to current long-term anticoagulation therapy and provide new revenue and atrial fibrillation treatment offerings for hospitals.
- Insertable Cardiac Monitors (ICMs). Externally worn Holter monitoring devices, historically the physicianpreferred method by physicians for detecting occasional difficult-to-identify cardiac arrhythmia events, seem to be falling by the wayside in favor of new insertable cardiac monitoring devices or ICMs. Medtronic’s product line of REVEAL DX™, REVEAL XT™ and REVEAL LINQ™ are the latest products hitting hospital shelves and wreaking havoc to cardiovascular service line directors’ budgets. Not much larger than a thumb-drive, ICMs can be inserted quickly and safely just under the skin in the cath lab to deliver clinical ECG readings for extended periods of time – up to three years.